NASDAQ · Biotechnology

PolyPid Ltd. (PYPD) Stock

$5.25 +2.34% NASDAQ: PYPD Healthcare

Valuation

MetricValue
Price$5.25
Market Cap$106.64M
P/E Ratio-3.51
P/B Ratio21.81
P/S Ratio0.00
EPS (TTM)$-2.09
52-Week High$5.73
52-Week Low$3.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-311.07%
ROA-206.78%
ROCE13.49%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.29
Current Ratio1.88

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-43.0M$-39.0M$-23.0M$-28.0M$-33.0M
Net Profit$-41.0M$-40.0M$-24.0M$-29.0M$-34.0M
EPS$-67.80$-61.20$-16.99$-4.91$-2.09
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$44.0M$26.0M$15.0M$25.0M$22.0M
Total Liabilities$8.0M$20.0M$17.0M$18.0M$11.0M
Cash$10.0M$9.0M$6.0M$16.0M$6.0M
Borrowings$0$14.0M$12.0M$10.0M$3.0M

Latest News

Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid GlobeNewswire · Jul 21, 2026 PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada GlobeNewswire · Jul 21, 2026 PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100 MT Newswires · Jun 1, 2026 PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ GlobeNewswire · Jun 1, 2026 PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference GlobeNewswire · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-34.0M$-17.0M$-22.0M$0
Investing Cash Flow$34.0M$15.0M$4.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$6.0M$-1.0M$-3.0M$10.0M$-9.0M
Free Cash Flow$-35.0M$-36.0M$-17.0M$-22.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-3.06
FCF Yield0.00%
Quick Ratio1.14
Interest Coverage48.50
Return 1Y50.43%
Return 3Y-55.00%
Return 5Y-97.77%

Ownership

Insiders Held21.23%
Institutions Held34.85%
Institutions Float Held44.24%
Institutional HolderSharesReport Date
AIGH Capital Management LLC1,593,5872026-03-31
Rosalind Advisors, Inc.597,9262026-03-31
DAFNA Capital Management, LLC207,9002026-03-31
Morgan Stanley176,8922026-03-31
J. Goldman & Co., L.P.149,4992026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVSAnnovis Bio, Inc. $1.00 +0.77% -0.56 $42.65M 0.00%
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.52 -5.00% 3.25 $47.79M 0.00%
BCAB $1.74 +0.00% -0.12 $2.88M 0.00%
BTAI $0.07 +0.00% -0.02 $2.28M 0.00%
CELUCelularity Inc. $0.98 -6.89% -0.46 $31.73M 0.00%

About PolyPid Ltd.

PolyPid Ltd. is led by CEO Dikla Czaczkes Akselbrad, employs 57 people, headquartered in IL, publicly traded since 2020.

PolyPid Ltd. (PYPD) stock trades at $5.25 with a market capitalization of $106.64M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.51, reflecting a net loss over the last twelve months, price-to-book of 21.81, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.06 and $5.73, and currently trades 8.4% below its 52-week high.

On profitability, PolyPid Ltd. generates a return on equity (ROE) of -311.07% (negative, reflecting a net loss), return on capital employed of 13.49%.

PolyPid Ltd. by the numbers, 2016–2025

Between 2016 and 2025 PolyPid Ltd. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-34.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-31.0M.

Borrowings stand at $3.0M, cash from operations was $0 in the latest year, positive in 0 of the last 10.

Return on equity has averaged -50.4% over five years, and was -309.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

PolyPid Ltd. (PYPD) — frequently asked questions

What is PolyPid Ltd. (PYPD) stock price today?

PolyPid Ltd. (PYPD) is currently trading at $5.25, up 2.34% today.

What is PYPD P/E ratio?

PolyPid Ltd.'s P/E ratio is -3.51. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is PYPD return on equity (ROE)?

PolyPid Ltd.'s return on equity (ROE) is -311.07%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is PolyPid Ltd.'s market cap?

PolyPid Ltd. has a market capitalization of $106.64M.

Does PYPD pay a dividend?

PolyPid Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does PYPD carry?

PolyPid Ltd. has a debt-to-equity ratio of 0.29. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is PYPD's profit margin?

PolyPid Ltd. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is PYPD in?

PolyPid Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is PYPD listed on?

PolyPid Ltd. trades on NASDAQ under the ticker PYPD.

What is PYPD's 52-week range?

Over the last year PolyPid Ltd. has traded between $3.06 and $5.73.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens PYPD currently matches

On the figures above, PolyPid Ltd. passes the filters for 1 of our ready-made screens, among them Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.